No observed benefit of adjuvant everolimus combined with endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer
1. Disease-free survival did not differ significantly between patient groups and overall survival at 3 years was the same for ...